在结肠直肠癌中,TIMP-2通过调节JAK-STAT信号通路来调节5-Fu抵抗
Chuchu Xu1, Renjun Zhu2, Qingfeng Dai3
1Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Journal of cellular and molecular medicine
|March 21, 2025
概括
组织金属蛋白酶2抑制剂 (TIMP-2) 通过激活JAK-STAT通路,驱动结肠直肠癌 (CRC) 中的5-Fluorouracil (5-Fu) 耐药性. 准TIMP-2或JAK-STAT可以克服这种化疗耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 抗5-fluorouracil (5-Fu) 耐药性是结直肠癌 (CRC) 治疗的一个主要挑战.
- 组织金属蛋白酶2抑制剂 (TIMP-2) 与CRC相关,但其在5-Fu耐药性中的作用尚不清楚.
研究的目的:
- 调查TIMP-2表达和CRC中的5-Fu抵抗之间的相关性.
- 阐明TIMP-2-介导的5-Fu抗性的潜在分子机制.
主要方法:
- 细胞因子阵列查以确定差异表达的细胞因子.
- 检测IC50和细胞增殖的CCK-8测定.
- 对于TIMP-2表达分析的ELISA和RT-qPCR.
- 西方涂抹评估信号通路蛋白质.
主要成果:
- 在5-Fu抵抗性CRC细胞系和患者血清中,TIMP-2表达显著升高.
- 发现TIMP-2通过JAK-STAT信号通路调解5-Fu电阻.
- 阻断TIMP-2或JAK-STAT通路可以逆转CRC细胞中的5-Fu抵抗.
结论:
- 通过JAK-STAT通路,TIMP-2在结直肠癌中介于5-Fu耐药性方面发挥着至关重要的作用.
- 准TIMP-2或JAK-STAT通路是一个有希望的治疗策略,以克服CRC中的5-Fu抵抗.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


